Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and AffloVest, a portable high frequency chest wall oscillation test for the treatment of retained pulmonary secretions such as bronchiectasis, cystic fibrosis, and various neuromuscular disorders. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.

Tactile Systems Technology, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MINNEAPOLIS, JULY 21, 2026 (GLOBE NEWSWIRE) -- TACTILE SYSTEMS TECHNOLOGY, INC. (TACTILE MEDICAL; THE COMPANY) (NASDAQ: TCMD), A MEDICAL TECHNOLOGY COMPANY PROVIDING THERAPIES FOR PEOPLE WITH CHRONIC DISORDERS, TODAY ANNOUNCED THAT SECOND QUARTER OF FISCAL YEAR 2026 FINANCIAL RESULTS WILL BE RELEASED AFTER THE MARKET CLOSES ON MONDAY, AUGUST 10, 2026.

TACTILE MEDICAL TO RELEASE SECOND QUARTER OF FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 10, 2026

DISCREET, BATTERY-POWERED DEVICE REACHES PATIENTS AT EARLIER STAGES OF DISEASE PROGRESSION DISCREET, BATTERY-POWERED DEVICE REACHES PATIENTS AT EARLIER STAGES OF DISEASE PROGRESSION

TACTILE MEDICAL ENTERS EXCLUSIVE U.S. DISTRIBUTION AGREEMENT WITH ELASTIMED FOR ITS MYOSLEEVE WEARABLE COMPRESSION DEVICE FOR VA AND DOD PATIENTS

MINNEAPOLIS, JUNE 02, 2026 (GLOBE NEWSWIRE) -- TACTILE SYSTEMS TECHNOLOGY, INC. (TACTILE MEDICAL; THE COMPANY) (NASDAQ: TCMD), A MEDICAL TECHNOLOGY COMPANY PROVIDING THERAPIES FOR PEOPLE WITH CHRONIC DISORDERS, TODAY ANNOUNCED FULL COMMERCIAL LAUNCH OF ITS NEXT-GENERATION AFFLOVEST HIGH-FREQUENCY CHEST WALL OSCILLATION (HFCWO) THERAPY SYSTEM. THE NEXT-GENERATION SYSTEM MAINTAINS ITS INDICATION FOR USE AS A TREATMENT OPTION FOR CHRONIC NEUROMUSCULAR AND RESPIRATORY CONDITIONS, INCLUDING CYSTIC FIBROSIS AND BRONCHIECTASIS, ACROSS PEDIATRIC AND GERIATRIC POPULATIONS, WHILE INTRODUCING ENHANCEMENTS TO PATIENT COMFORT, EASE OF USE, AND CONNECTED CARE CAPABILITIES TO SUPPORT LONG-TERM THERAPY ADHERENCE.

TACTILE MEDICAL LAUNCHES NEXT-GENERATION AFFLOVEST AIRWAY CLEARANCE THERAPY

MINNEAPOLIS, MAY 20, 2026 (GLOBE NEWSWIRE) -- TACTILE SYSTEMS TECHNOLOGY, INC. (TACTILE MEDICAL; THE COMPANY) (NASDAQ: TCMD), A MEDICAL TECHNOLOGY COMPANY PROVIDING THERAPIES FOR PEOPLE WITH CHRONIC DISORDERS, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN THE WILLIAM BLAIR 46TH ANNUAL GROWTH STOCK CONFERENCE, WHICH IS BEING HELD AT THE LOEWS HOTEL IN CHICAGO, IL, FROM JUNE 2-4, 2026. MANAGEMENT WILL PRESENT ON TUESDAY, JUNE 2, AT 9:20 A.M. CENTRAL TIME.

TACTILE MEDICAL TO PRESENT AT THE WILLIAM BLAIR 46TH ANNUAL GROWTH STOCK CONFERENCE

MINNEAPOLIS, MAY 04, 2026 (GLOBE NEWSWIRE) -- TACTILE SYSTEMS TECHNOLOGY, INC. (TACTILE MEDICAL; THE COMPANY) (NASDAQ: TCMD), A MEDICAL TECHNOLOGY COMPANY PROVIDING THERAPIES FOR PEOPLE WITH CHRONIC DISORDERS, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026. FIRST QUARTER 2026 SUMMARY AND RECENT BUSINESS HIGHLIGHTS: TOTAL REVENUE INCREASED 23% YEAR-OVER-YEAR TO $75.3 MILLION GROSS MARGIN OF 76.5% VERSUS 74% IN Q1 2025 NET LOSS OF $1.8 MILLION VERSUS $3.0 MILLION IN Q1 2025 ADJUSTED EBITDA OF $3.7 MILLION VERSUS AN ADJUSTED EBITDA LOSS OF $0.3 MILLION IN Q1 2025 EXPANDED AI-ENABLED ORDER MANAGEMENT PLATFORM WITH THE IMPLEMENTATION OF NEW OPERATIONAL CAPABILITIES TO EXECUTE THE MEDICARE PRIOR AUTHORIZATION REQUIREMENT FOR PCDS REPURCHASED $1.1 MILLION OF STOCK UNDER THE COMPANY'S SHARE REPURCHASE PROGRAM RECEIVED FDA 510(K) CLEARANCE FOR NEXT-GENERATION AFFLOVEST AIRWAY CLEARANCE DEVICE WE DELIVERED A STRONG START TO 2026, WITH FIRST QUARTER REVENUE GROWTH OF 23% YEAR-OVER-YEAR DRIVEN BY DISCIPLINED EXECUTION OF OUR STRATEGIC PRIORITIES, SAID SHERI DODD, CHIEF EXECUTIVE OFFICER OF TACTILE MEDICAL.

TACTILE SYSTEMS TECHNOLOGY, INC. REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

MINNEAPOLIS, APRIL 20, 2026 (GLOBE NEWSWIRE) -- TACTILE SYSTEMS TECHNOLOGY, INC. (TACTILE MEDICAL; THE COMPANY) (NASDAQ: TCMD), A MEDICAL TECHNOLOGY COMPANY PROVIDING THERAPIES FOR PEOPLE WITH CHRONIC DISORDERS, TODAY ANNOUNCED THAT FIRST QUARTER OF FISCAL YEAR 2026 FINANCIAL RESULTS WILL BE RELEASED AFTER THE MARKET CLOSES ON MONDAY, MAY 4, 2026.

TACTILE MEDICAL TO RELEASE FIRST QUARTER OF FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 4, 2026

MINNEAPOLIS, MARCH 09, 2026 (GLOBE NEWSWIRE) -- TACTILE SYSTEMS TECHNOLOGY, INC. (TACTILE MEDICAL; THE COMPANY) (NASDAQ: TCMD), A MEDICAL TECHNOLOGY COMPANY PROVIDING THERAPIES FOR PEOPLE WITH CHRONIC DISORDERS, TODAY ANNOUNCED THE APPOINTMENT OF ANDREA PEARSON TO THE COMPANY'S BOARD OF DIRECTORS (BOARD) AND AS A MEMBER OF THE COMPLIANCE & REIMBURSEMENT AND NOMINATING & CORPORATE GOVERNANCE COMMITTEES, EFFECTIVE MARCH 9, 2026.

TACTILE MEDICAL STRENGTHENS BOARD OF DIRECTORS WITH APPOINTMENT OF ANDREA PEARSON

MINNEAPOLIS, FEB. 17, 2026 (GLOBE NEWSWIRE) -- TACTILE SYSTEMS TECHNOLOGY, INC. (TACTILE MEDICAL; THE COMPANY) (NASDAQ: TCMD), A MEDICAL TECHNOLOGY COMPANY PROVIDING THERAPIES FOR PEOPLE WITH CHRONIC DISORDERS, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2025. FOURTH QUARTER 2025 SUMMARY: TOTAL REVENUE INCREASED 21% YEAR-OVER-YEAR TO $103.6 MILLION GROSS MARGIN OF 78% VERSUS 75% IN Q4 2024 NET INCOME OF $10.6 MILLION VERSUS $9.7 MILLION IN Q4 2024 ADJUSTED EBITDA OF $22.9 MILLION VERSUS $16.2 MILLION IN Q4 2024 FULL YEAR 2025 SUMMARY: TOTAL REVENUE INCREASED 12% YEAR-OVER-YEAR TO $329.5 MILLION GROSS MARGIN OF 76%, COMPARED TO 74% IN 2024 OPERATING CASHFLOW OF $42.8 MILLION, COMPARED TO $40.7 MILLION IN 2024 REPAID FULL OUTSTANDING PRINCIPAL BALANCE OF $26.3 MILLION UNDER THE COMPANY'S TERM LOAN REPURCHASED $26.5 MILLION OF STOCK AT AN AVERAGE PRICE OF $12.36 PER SHARE ENDED 2025 WITH $83.4 MILLION IN CASH, COMPARED TO $94.4 MILLION AT THE END OF 2024 RECENT BUSINESS HIGHLIGHTS ACQUIRED LYMPHATECH, EXPANDING OUR LYMPHEDEMA SOLUTIONS PORTFOLIO AND STRENGTHENING OUR R&D CAPABILITIES WITH THEIR DIGITAL 3D SCANNING TECHNOLOGY FOR CHRONIC SWELLING DETECTION, MEASUREMENT, AND MONITORING ANNOUNCED THE PUBLICATION OF TWO-MONTH CLINICAL DATA COMPARING FLEXITOUCH PLUS TO USUAL CARE IN THE JOURNAL OF THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK IN 2025, WE EXECUTED WITH DISCIPLINE AGAINST OUR CORE GROWTH STRATEGIES, DELIVERING DOUBLE-DIGIT REVENUE GROWTH, EXPANDING GROSS MARGIN AND ADJUSTED EBITDA, AND GENERATING STRONG CASH FLOW, WHILE CONTINUING TO STRATEGICALLY INVEST IN PEOPLE AND WORKFLOW-RELATED PROCESSES TO STRENGTHEN OUR BUSINESS FOR SCALE, SAID SHERI DODD, CHIEF EXECUTIVE OFFICER OF TACTILE MEDICAL.

TACTILE SYSTEMS TECHNOLOGY, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

LYMPHATECH'S 3D PLATFORM AND DIGITAL CAPABILITIES TO IMPROVE DISEASE IDENTIFICATION, ACCELERATE THERAPY ADOPTION, AND SUPPORT NEXT-GENERATION LYMPHATIC THERAPIES LYMPHATECH'S 3D PLATFORM AND DIGITAL CAPABILITIES TO IMPROVE DISEASE IDENTIFICATION, ACCELERATE THERAPY ADOPTION, AND SUPPORT NEXT-GENERATION LYMPHATIC THERAPIES

TACTILE MEDICAL ACQUIRES LYMPHATECH, EXPANDING BREADTH AND DEPTH OF ITS LYMPHEDEMA SOLUTIONS PORTFOLIO

MINNEAPOLIS, FEB. 03, 2026 (GLOBE NEWSWIRE) -- TACTILE SYSTEMS TECHNOLOGY, INC. (TACTILE MEDICAL; THE COMPANY) (NASDAQ: TCMD), A MEDICAL TECHNOLOGY COMPANY PROVIDING THERAPIES FOR PEOPLE WITH CHRONIC DISORDERS, TODAY ANNOUNCED THAT FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS WILL BE RELEASED AFTER THE MARKET CLOSES ON TUESDAY, FEBRUARY 17, 2026.

Tactile Systems Technology, Inc.

TCMD

Price

Financial Reports

No items found.

Press Releases

Tactile Systems Technology, Inc.

TCMD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

TCMD